Biogen

Sr Biostatistician/Principal Biostatistician

Posted on: 30 Jan 2021

Cambridge, MA

Job Description

Job Description

The Sr Biostatistician/Prinicpal Biostatistician is responsible for providing the statistical expertise for company products within one or more therapeutic areas, He/She participates in protocol development, analysis plans and file/report specifications, and reviews study setup activities including but not limited to randomization, CRFs and data edits and serves as lead biostatistician assigned project(s). This person performs statistical analyses, interprets statistical results, and prepares clinical study reports including integrated summaries for submissions as appropriate. He/she also assists in preparation of responses to statistical issues arising in regulatory or other legal settings, or from external development partners. He/She maintains liaison with clinical research personnel in order to identify and meet the statistical support required by the development strategy under the supervision of the Associate Director or Director. He/She also contributes to the long-term growth strategy of the department by participating in process improvement initiatives, keeping abreast of the current statistical methodology development, and providing mentorship to new/junior biostatisticians.

Principal Accountabilities:

1. Represent Biostatistics on Project Teams; provides statistical expertise to support clinical development objectives and strategy

2. Defines statistical methodology, analyzes data and reports results and contributes to the strategic planning and execution of the clinical development plan for the assigned project; trains and supervises contract statisticians and ensures the quality of their deliverables.

3. Assists responses to addressing statistical issues are part of regulatory, legal or other challenges to the companys products or processes; may represent Biostatistics in key meetings as assigned

4. Serves as peer reviewer for material authored or coauthored by other statisticians and other clinical research personnel, and acts as an internal consultant, as assigned, on broad statistical issues that impact on the pharmaceutical/Biotechnology industry

5. Participates in approved process improvement initiatives; mentors new/junior biostatisticians; keeps up to date current on statistical methodology and computing development. Conducts modelling and simulations as needed

LI-TG1

Qualifications

* PhD in Biostatistics/Statistics or equivalent
* Thorough understanding of statistical principles and clinical trial methodology with the ability to practice and implement them.
* Ability to provide technical solutions to a wide range of difficult problems. Solutions are innovative, thorough and practicable, and consistent with objectives.
* Working knowledge of medical/biological terminology and clinical trial designs and competitive landscape in relevant therapeutic areas.
* Conversant with SAS or other software programming, and detailed knowledge of SAS procedures as well as computing tools for modelling and simulations.
* Working knowledge of regulatory guidelines and Commercial needs relating to statistical analysis, study reports and statistical components of regulatory submissions.
* Able to manage multiple projects simultaneously, to manage conflicting priorities, and to be flexible when priorities change
* Able to write and present information effectively. Demonstrates leadership skills with effective communication including being able to explain methodology and consequences of decisions in lay terms; able to translate requests to meaningful and relevant hypotheses/statistical questions

Additional Information

All your information will be kept confidential according to EEO guidelines.

Biogen

Cambridge, MA

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies.

Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development.

The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.